New PDUFA goal date scheduled for September 29, 2022 to allow time to review additional data CAMBRIDGE, Mass.–(BUSINESS WIRE) June 3, 2022 — Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”)…Original Article
You may also like
Merus Receives FDA Extension of PDUFA for Zenocutuzumab
Ionis Announces FDA Acceptance of New Drug Application...
Dizal Submits New Drug Application to the U.S. FDA for...
Neurotech Provides Update on BLA for NT-501 as a...
Unicycive Therapeutics Announces U.S. FDA Acceptance...
Aldeyra Therapeutics Announces FDA Acceptance for...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.